GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » PS Ratio

Island Pharmaceuticals (ASX:ILA) PS Ratio : (As of Mar. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Island Pharmaceuticals's share price is A$0.155. Island Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00. Hence, Island Pharmaceuticals's PS Ratio for today is .

The historical rank and industry rank for Island Pharmaceuticals's PS Ratio or its related term are showing as below:

ASX:ILA' s PS Ratio Range Over the Past 10 Years
Min: 4.64   Med: 9.29   Max: 13.93
Current: 11.07

During the past 4 years, Island Pharmaceuticals's highest PS Ratio was 13.93. The lowest was 4.64. And the median was 9.29.

ASX:ILA's PS Ratio is ranked worse than
57.23% of 1003 companies
in the Biotechnology industry
Industry Median: 8.69 vs ASX:ILA: 11.07

Island Pharmaceuticals's Revenue per Sharefor the six months ended in Dec. 2024 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00.

Back to Basics: PS Ratio


Island Pharmaceuticals PS Ratio Historical Data

The historical data trend for Island Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals PS Ratio Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24
PS Ratio
- - - 5.50

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only - - - 5.50 -

Competitive Comparison of Island Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Island Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Island Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's PS Ratio falls into.



Island Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Island Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.155/0
=

Island Pharmaceuticals's Share Price of today is A$0.155.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Island Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Island Pharmaceuticals  (ASX:ILA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Island Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Island Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines